Sugi Predict

Sugi Predict / Compounds / SCHEMBL3261678

SCHEMBL3261678

SCHEMBL3261678

CC(C)(C)OC(=O)NCC1CCC(NC(=O)OCc2ccccc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.59
▸ GAA P10253 1/20 0.59
▸ TSHR P16473 1/20 0.57
▸ SYK P43405 1/20 0.52
▸ EPHX1 P07099 1/20 0.51
▸ ACACB O00763 5/20 0.50
▸ ACACA Q13085 3/20 0.50
▸ DRD2 P14416 2/20 0.50
▸ KMT2A Q03164 2/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ DPP4 P27487 1/20 0.47
▸ KCNH2 Q12809 1/20 0.47
▸ DPP7 Q9UHL4 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ ACHE P22303 1/20 0.47
▸ KDM1A O60341 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ MEN1 O00255 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3261676 1.00 ALDH1A1 (0.59) ALDH1A1GAATSHRSYKEPHX1
SCHEMBL3946631 0.95 ALDH1A1 (0.56) ALDH1A1GAATSHRSYKEPHX1
SCHEMBL3946595 0.95 ALDH1A1 (0.56) ALDH1A1GAATSHRSYKEPHX1
SCHEMBL7209388 0.95 ALDH1A1 (0.56) ALDH1A1GAATSHRSYKEPHX1
SCHEMBL6643790 0.93 ALDH1A1 (0.54) ALDH1A1GAATSHRSYKEPHX1
SCHEMBL13666981 0.92 SYK (0.57) SYKACACBACACADRD2KMT2A
SCHEMBL13668666 0.92 SYK (0.57) SYKACACBACACADRD2KMT2A
SCHEMBL30442637 0.90 ALDH1A1 (0.58) ALDH1A1GAATSHRSYKEPHX1
SCHEMBL6153463 0.89 ALDH1A1 (0.69) ALDH1A1GAATSHRSYKEPHX1
SCHEMBL3944464 0.89 ALDH1A1 (0.69) ALDH1A1GAATSHRSYKEPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-02-27 — — US disclosed
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-07-13 — — US disclosed
EP-4157849-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND Uppthera, Inc. (KR) 2023-04-05 — — EP disclosed
WO-2023018238-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 — — WO disclosed
WO-2023017446-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-02-16 — — WO disclosed
EP-1890703-B1 PYRIMIDINE COMPOUNDS AS CHEMOKINE RECEPTORS INHIBITORS TAIGEN BIOTECHNOLOGY CO LTD (TW) 2016-05-11 — — EP disclosed
US-8193206-B2 Pyrimidine compounds TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2012-06-05 — — US disclosed
US-8193206-B2 Pyrimidine compounds TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2012-06-05 — — US disclosed
WO-2010056847-A2 LYOPHILIZATION FORMULATION TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2010-05-20 — — WO disclosed
US-20100120719-A1 LYOPHILIZATION FORMULATION TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2010-05-13 — — US disclosed
EP-1183245-A1 SELECTIVE NPY (Y5) ANTAGONISTS SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2002-03-06 — — EP disclosed
EP-1182195-A1 CYCLIC COMPOUNDS AND USES THEREOF Takeda Chemical Industries, Ltd. (JP) 2002-02-27 — — EP disclosed
WO-2002006245-A1 SELECTIVE MELANIN CONCENTRATING HORMONE-1 (MCH1) RECEPTOR ANTAGONISTS AND USES THEREOF SYNAPTIC PHARMARCEUTICAL CORPORATION (US) 2002-01-24 — — WO disclosed
US-6225330-B1 Selective NPY (Y5) antagonists (tricyclics) SYNAPTIC PHARMACEUTICAL CORPORATION 2001-05-01 — — US disclosed
US-6222040-B1 FOR THERAPY OF EATING DISORDERS SYNAPTIC PHARMACEUTICAL CORPORATION 2001-04-24 — — US disclosed
US-6214853-B1 DIETETICS SYNAPTIC PHARMACEUTICAL CORPORATION 2001-04-10 — — US disclosed
WO-2001002379-A1 SELECTIVE NPY (Y5) ANTAGONISTS SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2001-01-11 — — WO disclosed
WO-2000064880-A1 SELECTIVE NPY (Y5) ANTAGONISTS SYNAPTIC PHARMACEUTICAL CORPORATION (US) 2000-11-02 — — WO disclosed
US-5821240-A ENZYME INHIBITORS, SIGNAL INHIBITORS FOR ANTIINFLAMMATORY AGENTS, ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS AND HORMONE INHIBITORS DR. KARL THOMAE GMBH (DE) 1998-10-13 — — US disclosed
WO-1997020823-A2 2-AMINO QUINAZOLINE DERIVATIVES AS NPY RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 1997-06-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219966-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 ALDH1A1 4008/4885GAA 2658/4885TSHR 3971/4885
US-20100120719-A1 LYOPHILIZATION FORMULATION DPYD, TYMP, TYMS ALDH1A1 1441/4885GAA 310/4885TSHR 2534/4885
US-11912710-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 ALDH1A1 2752/4885GAA 2669/4885TSHR 3869/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.